Skip to main content
. 2021 Jul 24;147(10):2993–3002. doi: 10.1007/s00432-021-03708-1

Fig. 2.

Fig. 2

PFS and OS in regorafenib plus DEB-TACE group and regorafenib group. A Comparison of PFS between regorafenib plus DEB-TACE group and regorafenib group; B comparison of OS between regorafenib plus DEB-TACE group and regorafenib group. PFS progression-free survival, OS overall survival, DEB-TACE drug-eluting beads-transarterial embolization, CI confidence interval